A detailed history of Fmr LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Fmr LLC holds 96,403 shares of EDIT stock, worth $376,935. This represents 0.0% of its overall portfolio holdings.

Number of Shares
96,403
Previous 77,618 24.2%
Holding current value
$376,935
Previous $575,000 21.74%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.67 - $7.28 $87,725 - $136,754
18,785 Added 24.2%
96,403 $450,000
Q1 2024

May 13, 2024

BUY
$7.03 - $11.07 $8,682 - $13,671
1,235 Added 1.62%
77,618 $575,000
Q4 2023

Feb 13, 2024

SELL
$6.25 - $11.11 $56,137 - $99,790
-8,982 Reduced 10.52%
76,383 $773,000
Q3 2023

Nov 13, 2023

BUY
$6.92 - $9.31 $41,852 - $56,306
6,048 Added 7.63%
85,365 $665,000
Q2 2023

Aug 11, 2023

BUY
$6.36 - $11.47 $158,701 - $286,210
24,953 Added 45.9%
79,317 $652,000
Q1 2023

May 11, 2023

BUY
$7.03 - $11.53 $2,474 - $4,058
352 Added 0.65%
54,364 $394,000
Q4 2022

Feb 13, 2023

SELL
$8.32 - $13.21 $18,087 - $28,718
-2,174 Reduced 3.87%
54,012 $479,000
Q3 2022

Nov 10, 2022

BUY
$12.16 - $19.42 $176,429 - $281,764
14,509 Added 34.81%
56,186 $688,000
Q2 2022

Aug 12, 2022

SELL
$9.99 - $21.35 $54,515 - $116,506
-5,457 Reduced 11.58%
41,677 $493,000
Q1 2022

May 13, 2022

SELL
$14.08 - $27.63 $649,975 - $1.28 Million
-46,163 Reduced 49.48%
47,134 $896,000
Q4 2021

Feb 14, 2022

SELL
$26.55 - $40.57 $5.71 Million - $8.72 Million
-215,050 Reduced 69.74%
93,297 $2.48 Million
Q3 2021

Nov 15, 2021

BUY
$39.27 - $72.94 $10.1 Million - $18.7 Million
256,330 Added 492.78%
308,347 $12.7 Million
Q2 2021

Aug 13, 2021

BUY
$31.29 - $56.64 $1.63 Million - $2.95 Million
52,017 New
52,017 $2.95 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $269M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Fmr LLC Portfolio

Follow Fmr LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.